Invivyd (NASDAQ:IVVD) Insider Sells $30,639.36 in Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Robert Allen III sold 19,392 shares of the company’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $1.58, for a total transaction of $30,639.36. Following the transaction, the insider owned 114,487 shares in the company, valued at $180,889.46. The trade was a 14.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Invivyd Trading Down 3.7%

IVVD stock opened at $1.55 on Friday. The firm has a 50 day moving average of $2.16 and a 200-day moving average of $1.76. The company has a market cap of $361.34 million, a price-to-earnings ratio of -3.30 and a beta of 0.60. Invivyd, Inc. has a 12-month low of $0.46 and a 12-month high of $3.07.

Institutional Trading of Invivyd

Institutional investors and hedge funds have recently made changes to their positions in the stock. Invesco Ltd. raised its stake in Invivyd by 67.6% in the 4th quarter. Invesco Ltd. now owns 293,580 shares of the company’s stock valued at $725,000 after purchasing an additional 118,411 shares during the last quarter. Ikarian Capital LLC grew its holdings in shares of Invivyd by 27.8% during the fourth quarter. Ikarian Capital LLC now owns 2,656,570 shares of the company’s stock worth $6,562,000 after buying an additional 577,864 shares in the last quarter. Virtus Investment Advisers LLC acquired a new position in shares of Invivyd in the fourth quarter valued at approximately $283,000. Quadrature Capital Ltd lifted its stake in shares of Invivyd by 98.3% during the fourth quarter. Quadrature Capital Ltd now owns 91,241 shares of the company’s stock valued at $225,000 after buying an additional 45,229 shares during the period. Finally, Perceptive Advisors LLC purchased a new position in shares of Invivyd during the fourth quarter valued at approximately $53,809,000. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on IVVD shares. HC Wainwright boosted their target price on Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a research note on Wednesday, January 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Invivyd in a research report on Monday, December 29th. Zacks Research raised shares of Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Finally, D. Boral Capital restated a “hold” rating on shares of Invivyd in a research report on Tuesday, November 25th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Invivyd presently has an average rating of “Hold” and an average target price of $8.00.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.